Perspectives on the Challenges of Alzheimer’s Disease

Alzheimer’s disease (AD) continues to be a global health crisis. Progress has been made in our understanding of the science of AD; however, there remains no currently effective treatment to delay the onset of or prevent the disease. In this CME Outfitters Snack, expert faculty will discuss cutting edge data that can be incorporated to meet the demands of managing complex patients in everyday clinical practice.

This activity offers CE credit for:

  1. Physicians (CME)
  2. Pharmacists (ACPE)
  3. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Tuesday, May 8, 2018

Faculty

 

Anand Kumar, MD Anand Kumar, MD
Lizzie Gilman Professor and Head
Department of Psychiatry
University of Illinois at Chicago College of MedicineChicago, IL

 

Charles B. Nemeroff, MD, PhD Charles B. Nemeroff, MD, PhD
Leonard M. Miller Professor and Chairman
Department of Psychiatry and Behavioral Sciences
Clinical Director, Center on Aging
Chief of Psychiatry, Jackson Memorial Hospital
Chief of Psychiatry, University of Miami Hospital
Professor of Biochemistry and Molecular Biology
Leonard M. Miller School of Medicine
University of Miami
Miami, FL

 

Statement of Need

Alzheimer’s disease (AD) continues to be a global health crisis. Progress has been made in our understanding of the science of AD; however, there remains no currently effective treatment to delay the onset of or prevent the disease.

The pathophysiological process of AD begins many years before clinically obvious symptoms appear. In addition, the concept of a pre-symptomatic or preclinical stage of AD is gaining acceptance in the medical community. Discussion of risk factors and careful assessments of individuals 60 or older can improve recognition and help direct treatment approaches.

In this CMEOutfitters Snack, expert faculty will discuss cutting edge data that can be incorporated to meet the demands of managing complex patients in everyday clinical practice.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Discuss the role and clinical utility of biomarkers and imaging for current and future use in the diagnosis and treatment of Alzheimer’s disease.
  • Describe the emerging science and therapies that will build tomorrow’s treatments for AD.

Financial Support

Supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Target Audience

Physicians, pharmacists, and other healthcare professionals managing patients with Alzheimer’s disease

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)TM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education .5 contact hours (0.05 CEUs) Universal Activity Number:
0376-0000-17-014-H01-P

Type: knowledge-based

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST21241 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Kumar has no disclosures to report.

Dr. Nemeroff has disclosed that he receives grants/research support from National Institutes of Health (NIH). He serves as a consultant to Bracket (Clintara); Fortress Biotech; Gerson Lehrman Group, Inc. (GLG) Healthcare & Biomedical Council; Lundbeck; Mitsubishi Tanabe Pharma Development America; Prismic Pharmaceuticals, Inc.; Sunovion Pharmaceuticals Inc.; Taisho Pharmaceutical Inc.; Takeda Pharmaceuticals North America, Inc.; Total Pain Solutions (TPS); Xhale, Inc. He is a stockholder of AbbVie Inc.; Bracket; Celgene Corporation; Intermediate Holding Corp.; Network Life Sciences Inc.; OPKO Health, Inc.; Seattle Genetics, Inc.; Titan Pharmaceuticals, Inc.; Xhale, Inc. He has patents for Method and devices for transdermal delivery of lithium (US 6,375,990B1); Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2). He serves on the scientific advisory boards of American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); Bracket (Clintara); Brain & Behavior Research Foundation (BBRF) (formerly National Alliance for Research on Schizophrenia and Depression [NARSAD]); Laureate Institute for Brain Research, Inc. RiverMend Health, LLC; Skyland Trail; Xhale, Inc. He serves on the board of directors for American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); GratitudeAmerica, Inc. He receives income sources or equity of $10,000 or more from American Psychiatric Publishing; Bracket (Clintara); Takeda Pharmaceuticals North America, Inc.; Xhale, Inc.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Sharon Tordoff, CHCP (planning committee) has no disclosures to report.

Jan Perez, CHCP (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS(877.263.7767).